| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRD2144 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nrd2144 |
| P698 | PubMed publication ID | 17080030 |
| P5875 | ResearchGate publication ID | 6716674 |
| P2093 | author name string | Solomon Nwaka | |
| Alan Hudson | |||
| P2860 | cites work | Finding cures for tropical diseases: is open source an answer? | Q21144737 |
| Identification of an antimalarial synthetic trioxolane drug development candidate | Q22061876 | ||
| Genome sequence of the human malaria parasite Plasmodium falciparum | Q22122524 | ||
| A breakthrough in R&D; for neglected diseases: new ways to get the drugs we need | Q24810470 | ||
| Designing drugs for parasitic diseases of the developing world | Q24816910 | ||
| Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria | Q25256957 | ||
| Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data | Q27640586 | ||
| Insights into antifolate resistance from malarial DHFR-TS structures | Q27641016 | ||
| Hit and lead generation: beyond high-throughput screening | Q28204526 | ||
| Drug development for neglected diseases: a deficient market and a public-health policy failure | Q28207953 | ||
| The price of innovation: new estimates of drug development costs | Q28212140 | ||
| Navigating chemical space for biology and medicine | Q28298611 | ||
| The impact of whole genome sequence data on drug discovery--a malaria case study | Q28364437 | ||
| Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis | Q28469010 | ||
| The druggable genome | Q29547361 | ||
| Global mapping of pharmacological space | Q29615876 | ||
| Comparative genomics of trypanosomatid parasitic protozoa | Q29617953 | ||
| Opportunities and Challenges in Antiparasitic Drug Discovery | Q29999214 | ||
| High-throughput crystallography for lead discovery in drug design. | Q30331190 | ||
| PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data | Q30760703 | ||
| High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase | Q31156888 | ||
| A clinical drug library screen identifies astemizole as an antimalarial agent | Q33248659 | ||
| Current strategies in the search for novel antiparasitic agents | Q33537033 | ||
| Computational methods for the prediction of 'drug-likeness' | Q33826560 | ||
| A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. | Q34228426 | ||
| The process of structure-based drug design | Q34266765 | ||
| Strategic emphases for tropical diseases research: a TDR perspective. | Q34960448 | ||
| Integration of virtual and high-throughput screening | Q34988235 | ||
| Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. | Q35077278 | ||
| Antimalarial drug discovery: old and new approaches | Q35541777 | ||
| Virtual drug discovery and development for neglected diseases through public-private partnerships | Q35605447 | ||
| Antimalarial drug discovery: efficacy models for compound screening | Q35790381 | ||
| Taking inventory: antibacterial agents currently at or beyond phase 1. | Q35903238 | ||
| The life and times of ivermectin - a success story | Q35954279 | ||
| High-throughput drug discovery: what can we expect from HTS? | Q36022300 | ||
| Antibiotics: where did we go wrong? | Q36022317 | ||
| RNAi-based discovery and validation of new drug targets in filarial nematodes | Q36056264 | ||
| Chemistry-to-gene screens in Caenorhabditis elegans | Q36085676 | ||
| Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines | Q36221234 | ||
| Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. | Q36477657 | ||
| TDR collaboration with the pharmaceutical industry | Q36490633 | ||
| Parasitology. Drugs to combat tropical protozoan parasites | Q39020119 | ||
| Research on infectious diseases requires better coordination | Q39398014 | ||
| The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans | Q44601138 | ||
| Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue | Q44964295 | ||
| Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei | Q46100258 | ||
| Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents | Q47866965 | ||
| Academia-industry partnerships in drug discovery. | Q53596183 | ||
| Health Innovation Networks to Help Developing Countries Address Neglected Diseases | Q56420403 | ||
| Comparative genomics of nematodes | Q61630640 | ||
| High-throughput screening in academia: the Harvard experience | Q75230087 | ||
| Invited Perspective: Screening in Academe: A Perspective on Implementation of University-Based Small Molecule Screening | Q79184621 | ||
| Public health. Gates Foundation picks winners in Grand Challenges in Global Health | Q81920097 | ||
| P433 | issue | 11 | |
| P921 | main subject | lead | Q708 |
| P304 | page(s) | 941-955 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Innovative lead discovery strategies for tropical diseases | |
| P478 | volume | 5 |
| Q36510734 | 2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials |
| Q21034114 | A "reverse pharmacology" approach for developing an anti-malarial phytomedicine |
| Q40541880 | A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by Leishmania donovani |
| Q28474728 | A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni |
| Q28475314 | A kernel for open source drug discovery in tropical diseases |
| Q35097813 | A monoallelic deletion of the TcCRT gene increases the attenuation of a cultured Trypanosoma cruzi strain, protecting against an in vivo virulent challenge |
| Q34669706 | A novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts |
| Q28476171 | A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility |
| Q28479211 | A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit |
| Q43106044 | ATP-dependent ligases in trypanothione biosynthesis--kinetics of catalysis and inhibition by phosphinic acid pseudopeptides |
| Q28546955 | Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni |
| Q58560098 | Activity of the antiarrhythmic drug amiodarone against () : an in vitro and in vivo approach |
| Q34290022 | Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds |
| Q92910941 | Activity of the sesquiterpene lactone goyazensolide against Trypanosoma cruzi in vitro and in vivo |
| Q38089167 | Advances in the discovery and development of trematocidal drugs |
| Q28475996 | Advancing drug innovation for neglected diseases-criteria for lead progression |
| Q39467299 | Algorithmic Mapping and Characterization of the Drug-Induced Phenotypic-Response Space of Parasites Causing Schistosomiasis |
| Q79888535 | Aligning pharmaceutical innovation with medical need |
| Q37331608 | Alkaloids with antiprotozoal activity. |
| Q59360236 | An Industry Perspective on Dengue Drug Discovery and Development |
| Q37069597 | An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein |
| Q35545776 | An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. |
| Q39602481 | Anthelmintic discovery and development in the animal health industry |
| Q42238354 | Anti-infectious drug repurposing using an integrated chemical genomics and structural systems biology approach. |
| Q58703394 | Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi |
| Q39003990 | Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need |
| Q50061317 | Antichagasic effect of crotalicidin, a cathelicidin-like vipericidin, found in Crotalus durissus terrificus rattlesnake's venom gland. |
| Q64107570 | Antileishmanial Evaluation of the Leaf Latex of , Aloin A/B, and Its Semisynthetic Derivatives against Two Species |
| Q28473835 | Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds |
| Q36276857 | Antiparasitic Effect of Vitamin B12 on Trypanosoma cruzi |
| Q37846890 | Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control |
| Q37333136 | Antiprotozoal activity of 1-phenethyl-4-aminopiperidine derivatives |
| Q58848333 | Antiprotozoal activity of dehydroabietic acid derivatives against Leishmania donovani and Trypanosoma cruzi |
| Q100412982 | Arg-substituted VmCT1 analogs reveals promising candidate for the development of new antichagasic agent |
| Q33962768 | Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment |
| Q28474428 | Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90 |
| Q50117680 | Bauerenol Acetate, the Pentacyclic Triterpenoid from Tabernaemontana longipes, is an Antitrypanosomal Agent. |
| Q34411824 | Binding modes of 2,4-diaminoquinazoline and 2,4-diaminopteridine analogs to P. falciparum dihydrofolate reductase enzyme: Molecular docking studies. |
| Q58860051 | Binding of pyrazole-based inhibitors to Mycobacterium tuberculosis pantothenate synthetase: docking and MM-GB(PB)SA analysis |
| Q33631637 | CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives |
| Q27306040 | Caspase dependent programmed cell death in developing embryos: a potential target for therapeutic intervention against pathogenic nematodes |
| Q39531590 | Challenges in drug discovery for novel antifilarials |
| Q34298863 | Characterization of a melamino nitroheterocycle as a potential lead for the treatment of human african trypanosomiasis |
| Q55604560 | Cheminformatics models for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase. |
| Q57157512 | Chemotherapy for Fighting Schistosomiasis: Past, Present and Future |
| Q107038883 | Cognate and cognitive ecopharmacognosy — in an anthropogenic era |
| Q28479294 | Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivo |
| Q30565638 | Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements |
| Q58636775 | Current and Future Strategies for Improving Drug Discovery Efficiency |
| Q36916045 | Cytotoxicity and In Vitro Antileishmanial Activity of Antimony (V), Bismuth (V), and Tin (IV) Complexes of Lapachol. |
| Q35103178 | Design and Synthesis of Novel Hybrid Molecules against Malaria |
| Q28543164 | Development and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni |
| Q35047048 | Development and validation of four Leishmania species constitutively expressing GFP protein. A model for drug discovery and disease pathogenesis studies |
| Q34674534 | Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases |
| Q33419478 | Development of a novel virtual screening cascade protocol to identify potential trypanothione reductase inhibitors |
| Q39348237 | Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major |
| Q33361565 | Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries |
| Q38152776 | Diagnosis and treatment of schistosomiasis in children in the era of intensified control |
| Q27671819 | Dihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein Crystallography |
| Q28828834 | Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis |
| Q48330948 | Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening. |
| Q35666558 | Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis. |
| Q37118507 | Distributed Drug Discovery, Part 1: linking academia and combinatorial chemistry to find drug leads for developing world diseases |
| Q28481694 | Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51 |
| Q55341853 | Docking-based inverse virtual screening: methods, applications, and challenges. |
| Q39126638 | Dose-response relationships and tegumental surface alterations in Opisthorchis viverrini following treatment with mefloquine in vivo and in vitro |
| Q33520500 | Dragonamide E, a modified linear lipopeptide from Lyngbya majuscula with antileishmanial activity |
| Q39264838 | Drug development to protozoan diseases |
| Q36012422 | Drug discovery for malaria: a very challenging and timely endeavor |
| Q27306843 | Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening |
| Q28475676 | Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis |
| Q26999453 | Drug repurposing and human parasitic protozoan diseases |
| Q34622554 | Drug strategies targeting CYP51 in neglected tropical diseases |
| Q21267230 | Drug target prediction and prioritization: using orthology to predict essentiality in parasite genomes |
| Q37031891 | Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis |
| Q61453550 | Effective Tetradentate Compound Complexes against spp. that Act on Critical Enzymatic Pathways of These Parasites |
| Q27646528 | Efficacy, Pharmacokinetics, and Metabolism of Tetrahydroquinoline Inhibitors of Plasmodium falciparum Protein Farnesyltransferase |
| Q41122063 | Efficient synthesis of (R)-harmonine--the toxic principle of the multicolored Asian lady beetle (Harmonia axyridis). |
| Q34297640 | Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment |
| Q35833805 | Evaluation of leishmanicidal activity and cytotoxicity of Ricinus communis and Azadirachta indica extracts from western Kenya: in vitro and in vivo assays |
| Q35367533 | Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones |
| Q41989175 | Experimental and Clinical Treatment of Chagas Disease: A Review. |
| Q44173044 | Functional characterization of both MAP kinases of the human malaria parasite Plasmodium falciparum by reverse genetics |
| Q36413024 | Gallic and ellagic acids: two natural immunomodulator compounds solve infection of macrophages by Leishmania major. |
| Q24635333 | Genomic-scale prioritization of drug targets: the TDR Targets database |
| Q38746177 | Glucose-6-phosphate dehydrogenase of trypanosomatids: characterization, target validation, and drug discovery |
| Q97531147 | Gold-Silver Bimetallic Nanoparticles Reduced with Herbal Leaf Extracts Induce ROS-Mediated Death in Both Promastigote and Amastigote Stages of Leishmania donovani |
| Q34397745 | Hierarchical virtual screening for the discovery of new molecular scaffolds in antibacterial hit identification |
| Q38599011 | Hit and lead criteria in drug discovery for infectious diseases of the developing world |
| Q64112610 | IVS2vec: A tool of Inverse Virtual Screening based on word2vec and deep learning techniques |
| Q28544017 | Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign |
| Q33636074 | Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties |
| Q21144522 | Identification of attractive drug targets in neglected-disease pathogens using an in silico approach |
| Q24642230 | Identification of oxadiazoles as new drug leads for the control of schistosomiasis |
| Q36802656 | Identification of plumbagin and sanguinarine as effective chemotherapeutic agents for treatment of schistosomiasis |
| Q33529414 | Identification of small-molecule scaffolds for p450 inhibitors |
| Q90631946 | Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development |
| Q90594893 | In Vitro and In Vivo Studies of Spironolactone as an Antischistosomal Drug Capable of Clinical Repurposing |
| Q37149494 | In vitro activity of salinomycin and monensin derivatives against Trypanosoma brucei |
| Q43080976 | In vitro and in vivo experimental models for drug screening and development for Chagas disease |
| Q36213275 | In vitro and in vivo studies of the trypanocidal activity of four terpenoid derivatives against Trypanosoma cruzi |
| Q39219186 | In vitro antileishmanial activity and iron superoxide dismutase inhibition of arylamine Mannich base derivatives. |
| Q34240708 | In vitro antiplasmodial, antileishmanial and antitrypanosomal activities of selected medicinal plants used in the traditional Arabian Peninsular region |
| Q28536688 | In vitro susceptibilities of wild and drug resistant leishmania donovani amastigote stages to andrographolide nanoparticle: role of vitamin E derivative TPGS for nanoparticle efficacy |
| Q42374556 | In vivo anti-malarial activity and toxicity studies of triterpenic esters isolated form Keetia leucantha and crude extracts |
| Q30386961 | In vivo curative and protective potential of orally administered 5-aminolevulinic acid plus ferrous ion against malaria. |
| Q27652313 | Inhibition ofMycobacterium tuberculosisPantothenate Synthetase by Analogues of the Reaction Intermediate |
| Q41018677 | Inhibitory effect of a new orally active cedrol-loaded nanostructured lipid carrier on compound 48/80-induced mast cell degranulation and anaphylactic shock in mice |
| Q28477241 | Innovative partnerships for drug discovery against neglected diseases |
| Q28478485 | Integrated dataset of screening hits against multiple neglected disease pathogens |
| Q58867734 | Integrating and Mining Helminth Genomes to Discover and Prioritize Novel Therapeutic Targets |
| Q33305360 | Ivermectin resistance in Onchocerca volvulus: toward a genetic basis |
| Q36874745 | Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis |
| Q26786761 | Kinases as druggable targets in trypanosomatid protozoan parasites |
| Q36513308 | Kinetoplastids: related protozoan pathogens, different diseases |
| Q58914666 | Leishmanicidal activity of nine novel flavonoids from Delphinium staphisagria |
| Q33309109 | Lessons learnt from assembling screening libraries for drug discovery for neglected diseases |
| Q37098733 | Lipid metabolism in Trypanosoma brucei |
| Q46642960 | Making a difference: 30 years of TDR. |
| Q34443655 | Management of visceral leishmaniasis in rural primary health care services in Bihar, India |
| Q28474353 | Mefloquine--an aminoalcohol with promising antischistosomal properties in mice |
| Q34040586 | Megazol and its bioisostere 4H-1,2,4-triazole: comparing the trypanocidal, cytotoxic and genotoxic activities and their in vitro and in silico interactions with the Trypanosoma brucei nitroreductase enzyme |
| Q28540193 | Memantine, an antagonist of the NMDA glutamate receptor, affects cell proliferation, differentiation and the intracellular cycle and induces apoptosis in Trypanosoma cruzi |
| Q39076702 | Mission possible |
| Q38807251 | Modern approaches to accelerate discovery of new antischistosomal drugs. |
| Q37175168 | Molecular analysis of early host cell infection by Trypanosoma cruzi |
| Q41462661 | Molecular docking and molecular dynamics study on SmHDAC1 to identify potential lead compounds against Schistosomiasis |
| Q43186796 | More medicines for neglected and emerging infectious diseases |
| Q28485165 | Naphthoquinone derivatives exert their antitrypanosomal activity via a multi-target mechanism |
| Q90311503 | Natural Occurrence in Venomous Arthropods of Antimicrobial Peptides Active against Protozoan Parasites |
| Q21563416 | New approaches to filling the gap in tuberculosis drug discovery |
| Q38537004 | New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment. |
| Q53698713 | New endoperoxides highly active in vivo and in vitro against artemisinin-resistant Plasmodium falciparum. |
| Q35388295 | Northalrugosidine is a bisbenzyltetrahydroisoquinoline alkaloid from Thalictrum alpinum with in vivo antileishmanial activity |
| Q38891993 | Novel Heteroaryl Selenocyanates and Diselenides as Potent Antileishmanial Agents. |
| Q37742177 | Novel carbazole aminoalcohols as inhibitors of β-hematin formation: Antiplasmodial and antischistosomal activities. |
| Q39126651 | Opisthorchis viverrini: efficacy and tegumental alterations following administration of tribendimidine in vivo and in vitro |
| Q27660249 | Optimization of the Interligand Overhauser Effect for Fragment Linking: Application to Inhibitor Discovery against Mycobacterium tuberculosis Pantothenate Synthetase |
| Q57525861 | PDISC – Towards a Method for Software Product DISCovery |
| Q30977203 | Patenting bioactive molecules from biodiversity: the Brazilian experience |
| Q46921243 | Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni |
| Q66680575 | Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis |
| Q37777113 | Praziquantel and schistosomiasis. |
| Q39092348 | Preclinical drug evaluation system in the Plasmodium knowlesi baboon model of malaria: the methotrexate study |
| Q37487578 | Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development. |
| Q35864886 | Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites |
| Q37912232 | Progress and challenges in the discovery of macrofilaricidal drugs |
| Q90131075 | Promethazine exhibits antiparasitic properties in vitro and reduces worm burden, egg production, hepato-, and splenomegaly in a schistosomiasis animal model |
| Q34173302 | Quantification and clustering of phenotypic screening data using time-series analysis for chemotherapy of schistosomiasis. |
| Q38088306 | Recent initiatives and strategies to developing new drugs for tropical parasitic diseases |
| Q33530297 | Repositioning of an existing drug for the neglected tropical disease Onchocerciasis |
| Q39004171 | Repurposing pharma assets: an accelerated mechanism for strengthening the schistosomiasis drug development pipeline |
| Q92292385 | Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi |
| Q33385477 | Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria |
| Q36917998 | SM-TF: A structural database of small molecule-transcription factor complexes |
| Q39381400 | Schistosomes: challenges in compound screening |
| Q39560746 | Screening of agelasine D and analogs for inhibitory activity against pathogenic protozoa; identification of hits for visceral leishmaniasis and Chagas disease. |
| Q58782190 | Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell |
| Q27680126 | Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni |
| Q37409571 | Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis |
| Q50874149 | Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease. |
| Q37356679 | Structure-based ligand design and the promise held for antiprotozoan drug discovery. |
| Q34761978 | Structure-based systems biology for analyzing off-target binding |
| Q35012968 | Structures, targets and recent approaches in anti-leishmanial drug discovery and development |
| Q55645836 | Study of the activity of 3-benzyl-5-(4-chloro-arylazo)-4-thioxo-imidazolidin-2-one against Schistosomiasis mansoni in mice. |
| Q34088830 | Synthesis and evaluation of 1-(1-(Benzo[b]thiophen-2-yl)cyclohexyl)piperidine (BTCP) analogues as inhibitors of trypanothione reductase |
| Q35563920 | Synthesis and evaluation of the antiplasmodial activity of tryptanthrin derivatives |
| Q46160457 | Synthesis of limonene beta-amino alcohol derivatives in support of new antileishmanial therapies |
| Q40109825 | Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents |
| Q35630942 | TDR Targets: a chemogenomics resource for neglected diseases |
| Q60053808 | TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling |
| Q34301994 | Target assessment for antiparasitic drug discovery |
| Q35178447 | Target repurposing for neglected diseases |
| Q35237566 | Target validation: linking target and chemical properties to desired product profile |
| Q39003333 | Target-based molecular modeling strategies for schistosomiasis drug discovery. |
| Q52578236 | Targeting a Subpocket in Trypanosoma brucei Phosphodiesterase B1 (TbrPDEB1) Enables the Structure-Based Discovery of Selective Inhibitors with Trypanocidal Activity. |
| Q37120118 | Targeting the Cytochrome bc1 Complex of Leishmania Parasites for Discovery of Novel Drugs |
| Q83761418 | The African Network for Drugs and Diagnostics Innovation |
| Q39085289 | The Concept Paper on the Helminth Drug Initiative. Onchocerciasis/lymphatic filariasis and schistosomiasis: opportunities and challenges for the discovery of new drugs/diagnostics |
| Q90472214 | The Pseudomonas aeruginosa product pyochelin interferes with Trypanosoma cruzi infection and multiplication in vitro |
| Q28548328 | The Validation of Nematode-Specific Acetylcholine-Gated Chloride Channels as Potential Anthelmintic Drug Targets |
| Q36018855 | The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria |
| Q37001435 | The challenges of developing novel antiparasitic drugs |
| Q90178443 | The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi |
| Q28476644 | The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing |
| Q37053148 | Therapeutic effect of mefloquine on Schistosoma mansoni in experimental infection in mice |
| Q35036307 | Thiadiazine derivatives as antiprotozoal new drugs |
| Q35535825 | Thioredoxin glutathione reductase: its role in redox biology and potential as a target for drugs against neglected diseases. |
| Q36185174 | Threats from emerging and re-emerging neglected tropical diseases (NTDs). |
| Q27690713 | Traditional medicines as a mechanism for driving research innovation in Africa |
| Q30044443 | Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum |
| Q27008593 | Trypanocidal activity of marine natural products |
| Q39724954 | Trypanocidal activity of salinomycin is due to sodium influx followed by cell swelling |
| Q42559886 | Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib |
| Q58854975 | Trypanocidal and cysteine protease inhibitory activity of isopentyl caffeate is not linked in Trypanosoma brucei |
| Q27653636 | Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit |
| Q83171038 | Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms |
| Q38015506 | Understanding and creating value from open source drug discovery for neglected tropical diseases |
| Q30368852 | Using structural analysis to generate parasite-selective monoclonal antibodies. |
| Q38188571 | Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? |
| Q55415371 | Which Plants Used in Ethnomedicine Are Characterized? Phylogenetic Patterns in Traditional Use Related to Research Effort. |
| Q42130947 | Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis? |
Search more.